1 – 5 of 5
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
(
- Contribution to journal › Article
- 2011
-
Mark
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy
(
- Contribution to journal › Article
- 2010
-
Mark
Effects of AZD0837, a Novel Direct Thrombin Inhibitor, on the Electrophysiological Properties of the Human Heart A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study
(
- Contribution to journal › Article
- 2009
-
Mark
A Phase 2 Feasibility Trial of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation, Who Are Unable or Unwilling to Take Warfarin Therapy
(
- Contribution to journal › Published meeting abstract
-
Mark
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists
(
- Contribution to journal › Article